HomeAnalysisMaharashtra Moves to Add SMA Treatment to Public Health Scheme

Maharashtra Moves to Add SMA Treatment to Public Health Scheme

Maharashtra has directed its health department to begin the process of including spinal muscular atrophy (SMA) treatment under the Mahatma Jyotirao Phule Jan Arogya Yojana, a move aimed at reducing financial barriers for patients with the rare genetic disorder.

Deputy Chief Minister Eknath Shinde issued the directions at a meeting in the state legislature on rare-disease treatment systems. He also asked the health department to prepare a separate standard operating procedure (SOP) covering early diagnosis, patient registration, treatment and the regular availability of medicines.

The report by Loksatta said the proposed process is intended to prevent delays in care and ensure that patients do not lose access to treatment because of their family’s financial circumstances. SMA treatments are expensive, and the cost can place a substantial burden on households, according to the report.

The directions include simplifying registration and diagnosis procedures for SMA patients and ensuring a regular supply of oral medicines. The health department has been asked to prepare an action plan, but the report does not specify a deadline for completing the inclusion process or confirm when the benefits would become available under the scheme.

The meeting was attended by senior officials from the Deputy Chief Minister’s office and the health department, along with paediatric specialists from Wadia Hospital and KEM Hospital and representatives of the Jija social organisation.

KEM Hospital in Mumbai has been selected by the Union government as Maharashtra’s Centre of Excellence for rare diseases. The centre is responsible for supporting diagnosis, patient registration and treatment arrangements for rare diseases. The state government’s proposed SOP would create a defined pathway for SMA patients through these stages, although its final provisions have not yet been announced.

For families seeking care, the practical impact will depend on whether the proposed inclusion is formally approved, how eligibility is defined and how quickly medicines and diagnostic services can be accessed. The report records an administrative direction to begin that work, rather than a completed expansion of scheme coverage.


RELATED ARTICLES

Most Popular

Latest News